Human Gingiva-Derived Mesenchymal Stromal Cells Inhibit Graft-Versus-Host Disease Through CD39 and IDO.

M. Chen,J. Gu,D. Wang,W. Ju,H. Zadeh,S. Zheng,X. He,Z. Guo

DOI: https://doi.org/10.1097/00007890-201407151-01378

2016-01-01

The Journal of Immunology

Abstract:Mesenchymal stem cells (MSCs) have the capacity to maintain immune homeostasis and prevent autoimmunity. However, it is unclear whether human-derived gingival mesenchymal stem cells (GMSCs) can suppress human T cell-mediated diseases. GMSCs were isolated from human gingival tissues. GMSCs were cultured with allogeneic T cells which labeled with CFSE, and cell proliferation was evaluated by CFSE dilution in FACS. In other experiments, human PBMCs were stimulated with LPS with a ratio of PBMCs to GMSCs at 1:5. After 3 days, intracellular cytokine including IL-4, IL-17, and IFN-γ in CD4+ cells were determined by FACS. Mouse xeno-GVHD Model was induced in NOD/SCID mice, GMSCs or human fibroblasts (negative control) or human bone marrow mesenchymal stem cells (positive control) were intravenously into mice. Weight loss and symptoms of GVHD were assessed. We observed that GMSCs potently suppress the proliferation of T cells and differentiation of PBMC in vitro, and that co-transfer of GMSC but not fibroblast and human PBMC significantly prolonged xeno-GVHD mouse survival. We also demonstrated that GMSC is even better than BMSC on treating xeno-GVHD. We further revealed that GMSCs inhibit human PBMCs-initiated xenogenic responses via CD39 and IDO signals. GMSCs can suppress human immune responses and immune system-mediated diseases, offering a potential clinical option to be used for modulating GVHD and other autoimmune diseases.